Dr. Garovoy was a Professor of Surgery, Medicine and Laboratory Medicine at the University of California, San Francisco as well as an Assistant Professor of Medicine at Harvard Medical School. In addition, Dr. Garovoy has served as a Major and a transplant nephrologist in the United States Air Force. He is widely published having authored 178 peer-reviewed papers, 45 chapters and two books. Dr. Garovoy has five issued patents.“In the seven months I’ve served as Acting Chief Medical Officer, my conviction that Medgenics offers a completely new paradigm for the sustained production and delivery of protein therapies has increased. The Biopump technology holds promise to improve the healthcare of millions of people and could be truly transformative for patients, their physicians and payers. I am excited to be a part of the Medgenics team and look forward to working toward bringing these treatments to market,” commented Dr. Garovoy. About Medgenics Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own skin biopsy for the treatment of a range of chronic diseases including anemia, hepatitis, and hemophilia, among others. Medgenics believes this approach has multiple benefits compared with current treatments, which include regular and costly injections of therapeutic proteins. Medgenics has three long-acting protein therapy products in development based on this technology:
- EPODURE™ to produce and deliver erythropoietin for many months from a single administration, which has demonstrated elevation and stabilization of hemoglobin levels in anemic patients for periods of six months to more than 36 months in a Phase I/II dose-ranging trial in Israel and has launched a Phase IIa trial in dialysis patients in Israel. An Investigational New Drug application has been cleared by the FDA to initiate a Phase IIb study to evaluate the safety and efficacy of EPODURE in the treatment of anemia in dialysis patients in the U.S.
- INFRADURE™ for sustained production and delivery of interferon-alpha for use in the treatment of hepatitis is awaiting final approval of the Israeli Ministry of Health of two Phase I/II trials in Israel in hepatitis C, slated to commence Q3 2012; and which received Orphan Drug Designation from the FDA for the treatment of hepatitis D.
- HEMODURE™ for sustained production and delivery of clotting Factor VIII therapy for the sustained prophylactic treatment of hemophilia is in development.